Clinical Trial

Clinical Trial of PCV13 in Infants Aged Approximately 2 Months (42 to 89 Days)

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
A Phase III clinical trial of 13-valent pneumococcal conjugate vaccine (PCV13)developed by Sinovac Life Science Co., Ltd will be conducted in infants aged approximately 2 months (42 to 89 days). The objective of the study is to evaluate the immunogenicity and safety of Sinovac PCV13. The trial is a randomized, double-blind, active controlled phase III clinical trial.
Trial Details
NCT Number NCT07593924
Lead Sponsor Sinovac Life Sciences Co., Ltd.
Conditions Pneumococcal Infectious Diseases
Enrollment 500 participants
Start Date 2026-05
Primary Completion 2027-07 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2026-05-18